Chemistry:O-2050

From HandWiki
Short description: Chemical compound
O-2050
O-2050 structure.png
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC23H31NO4S
Molar mass417.56 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)

O-2050 is a drug that is a classical cannabinoid derivative, which acts as an antagonist for the CB1 receptor. This gives it an advantage in research over many commonly used cannabinoid antagonists, such as rimonabant, which at higher doses act as inverse agonists at CB1 as well as showing off-target effects. However, while O-2050 acts as a silent antagonist in vitro, some tests in vivo have suggested it may show agonist activity under certain circumstances.[1][2][3][4][5][6]

See also

References

  1. "Agonists and silent antagonists in a series of cannabinoid sulfonamides". 12th Annual Symposium on the Cannabinoids. 2002. http://cannabinoidsociety.org/HTML/ICRS.2002.symposium.pdf. 
  2. Martin, Billy R.; Raj K. Razdan & Roger G Pertwee, "Sulfonamide cannabinoid agonists and antagonists", US patent 7279500, published 2007-10-09
  3. "Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'". European Journal of Pharmacology 530 (1–2): 103–6. January 2006. doi:10.1016/j.ejphar.2005.11.032. PMID 16380113. 
  4. "The cannabinoid 1-receptor silent antagonist O-2050 attenuates preference for high-fat diet and activated astrocytes in mice". Journal of Pharmacological Sciences 112 (3): 369–72. 2010. doi:10.1254/jphs.09326sc. PMID 20168044. 
  5. "Increment of hypothalamic 2-arachidonoylglycerol induces the preference for a high-fat diet via activation of cannabinoid 1 receptors". Behavioural Brain Research 216 (1): 477–80. January 2011. doi:10.1016/j.bbr.2010.08.042. PMID 20817042. 
  6. "Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist". European Journal of Pharmacology 651 (1–3): 96–105. January 2011. doi:10.1016/j.ejphar.2010.10.085. PMID 21114999.